GlassScriptPhysician profile
Casey J Page
NPI 1215933577
$81,951.43
in general payments reported to CMS, 2019-2025
56 companies · $159 in 2025
The $159 reported for 2025 was less than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $25K · 2020: $13K · 2021: $28K · 2022: $11K · 2023: $2,128 · 2024: $2,241 · 2025: $159.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,508 · Education: $20.22.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,507.71 |
| Education | $20.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $55,662.78 | 2019-2024 | Rybelsus, Ozempic, Sogroya |
| Merck Sharp & Dohme LLC | $9,688.63 | 2019-2021 | |
| Tandem Diabetes Care, INC. | $7,482.58 | 2019-2022 | |
| Lilly USA, LLC | $962.13 | 2019-2024 | Jardiance, Mounjaro, Lyumjev |
| Mannkind Corporation | $651.02 | 2019-2025 | Afrezza |
| Amgen INC. | $628.31 | 2019-2024 | Tepezza, Repatha, Prolia |
| Xeris Pharmaceuticals, INC. | $610.31 | 2021-2025 | Gvoke Hypopen, Recorlev |
| Corcept Therapeutics | $572.60 | 2019-2024 | Korlym |
| Dexcom, INC. | $532.85 | 2019-2024 | Dexcom G6 Transmitter |
| Sanofi-Aventis U.S. LLC | $514.67 | 2019-2024 | |
| Abbott Laboratories | $460.01 | 2021-2024 | Freestyle Libre 3, Bigfoot Unity Diabetes Management System |
| Bayer Healthcare Pharmaceuticals INC. | $450.18 | 2021-2025 | |
| Insulet Corporation | $407.44 | 2019-2025 | Omnipod |
| Medtronic, INC. | $381.35 | 2021-2024 | Minimed 780g, Intellis Adaptivestim |
| Horizon Therapeutics Plc | $335.85 | 2020-2023 | Tepezza |
Show all 56 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Casey Page listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.